Mesylate apatinib (YN968D1) is a novel oral micromolecular tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), mainly through competitively binding the intracellular tyrosine in the adenosine triphosphate binding site of the receptor, thus highly selectively inhibiting the activity of the VEGFR-2 tyrosine kinase and blocking signal transduction after binding of vascular endothelial growth factor (VEGF), thereby potently inhibiting tumor angiogenesis and decreasing the density of microvessels in tumors19–21. This evidence concerns the gene VEGFA and neoplasm.